Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume
The filing is backed by positive Phase 3 results recently published in JAMA Neurology
First-in-human study of investigational SOS1 inhibitor shows encouraging safety profile and early anti-tumor activity in patients with metastatic solid tumors
The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
The investigational therapy, ifinatamab deruxtecan, is a potential first-in-class B7-H3 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and jointly developed with Merck
Lonza will take on technology transfer, process optimization, and cGMP manufacturing, leveraging its global network and expertise in highly potent compounds
Bocunebart works by blocking pituitary adenylate cyclase-activating polypeptide
The pioneering monoclonal antibody is for Essential Thrombocythemia (ET) and Polycythemia Vera (PV), rare chronic blood cancers with limited treatment options
CARsgen is working to transform outcomes for patients with solid tumors by advancing the potential of CAR T technologies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
